# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $58 price ta...
- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome- Lon...
HC Wainwright & Co. reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $58 price target.
Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p<0.0001) reduction in prurit...
Presented by Professor Richard J. Thompson, MD, King's College London, United Kingdom Patients with PFIC showed significan...
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and lowers the price targ...
JMP Securities analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers t...
Citigroup analyst David Lebovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $...